Home » 2007 » Volume 9 - Number 4 » Elite HIV Controllers: Myth or Reality?
Nitin K. Saksena 1, Berta Rodes 1, Bin Wang 1, Vicente Soriano 2
1 NULL; 2 UNIR Health Sciences School and Medical Center, Universidad Internacional de La Rioja, Madrid, Spain
*Correspondence: Berta Rodes, Email not available
Despite the varying disease progression rates, the majority of HIV-infected individuals eventuallyprogress to AIDS. There is a subset of HIV-positive individuals, who maintain high CD4+ and CD8+T-cell counts, remain therapy naive and persistently infected with HIV-1 for more than 15 to 20 years.In light of current observations, this subset can be divided into two groups. One shows low detectableplasma viremia (< 5000 HIV-RNA copies/ml), termed long-term nonprogressors. A second groupshows plasma HIV-RNA values persistently below 50 copies/ml throughout the course of infection,and termed âeliteâ? or ânatural controllersâ?. The features common between both groups are the presenceof high CD4+ and CD8+ T-cell counts, strong immune responses, and low but variable cellularproviral DNA load. The group of HIV-positive long-term nonprogressor individuals comprises about1% of the total HIV population in the world, whereas the âeliteâ? controllers may be much less. Whydo some people deteriorate faster, while others remain normal both symptomatically and immunologicallyfor decades? There is a renewed interest in HIV-positive individuals who have survived sincethe period close to the earlier part of the HIV pandemic in the 1980s and have remained drug-naive.As very little is known about âeliteâ? controllers, the findings discussed here are largely based onpreviously known and newly emerging aspects of HIV pathogenesis in the context of the long-termnonprogressor group. It is believed that data emerging on long-term nonprogressors will allow us tomake scientific inferences to further our research on âeliteâ? controllers. Aspects dealing with cellular,humoral, innate, and adaptive immunity, which are relevant to nonprogressive HIV disease, are beyondthe scope of this review.